Fresenius Kabi’s Idacio (adalimumab, biosimilar) Receives EU’s Marketing Approval in Rheumatology, Gastroenterology and Dermatology

 Fresenius Kabi’s Idacio (adalimumab, biosimilar) Receives EU’s Marketing Approval in Rheumatology, Gastroenterology and Dermatology

Fresenius Kabi’s Idacio (adalimumab, biosimilar) Receives EU’s Marketing Approval in Rheumatology, Gastroenterology and Dermatology

Shots:

  • The approval is based on its non-inferiority data consisting of its PK, efficacy, safety, immunogenicity data with the reference product in analytical, preclinical and clinical data trials
  • Fresenius Kabi has a portfolio consisting of generic drugs, infusion therapies, biosimilars, and clinical nutrition products focusing on multiple therapy areas
  • Idacio (adalimumab, biosimilar) is a mAb and is indicated for Rheumatoid arthritis (RA), Juvenile Idiopathic Arthritis, Axial Spondyloarthritis, psoriatic arthritis, plaque psoriasis, adult & pediatric Crohn’s disease and ulcerative colitis

Click here to read full press release/ article | Ref: Fresenius Kabi | Image: Behance

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post